# FDA Risk

> FDA Risk collects clear, sourced facts from published research on FDA drug and device oversight: inspections, warning letters, and what drives quality risk at suppliers. Each fact links to the paper it came from. FDA Risk is powered by KeyPedia, where the underlying FDA records can be searched free in KeyPedia Lite.

Every number below appears in the cited paper's published abstract or published full text. Simulation results and illustrations are labeled as such.

## Lead finding

### 23 fewer FDA inspections for every extra $1B in drug imports

Imports rose. Foreign inspections fell.

- Data (FDA inspections in China per $1B of drug imports, decline, 2014 to 2024: 82%):
  - 2014: 101.8
  - 2024: 18.3
- China only. The headline covers all U.S. drug imports, 2014 to 2019.
- Source: George Kwiecinski and Kevin Yuan. "The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014–2024." Journal of Pharmaceutical Innovation, 2026. https://doi.org/10.1007/s12247-026-10406-3
- Basis: Published abstract (Crossref), Results and Conclusion.

## What the research shows

Facts are listed oldest research first.

### Decay, then reset: Quality routines slip between FDA inspections. Each inspection halts the slide.

- Data (Illustration of the finding, not data):
  - Schematic: a line for quality routines declines steadily, then jumps back up at each FDA inspection.
- Source: Gopesh Anand, John V. Gray, and Enno Siemsen. "Decay, Shock, and Renewal: Operational Routines and Process Entropy in the Pharmaceutical Industry." Organization Science, 2012. https://doi.org/10.1287/orsc.1110.0709
- Basis: Published abstract (qualitative finding). Drawn as a schematic, not data.

### $569M+ average loss to a drug maker from one FDA safety relabeling, up to $882M

- Data (Event study of FDA safety relabeling. Dashed: upper estimate.):
  - Product sales, $186M; Future innovation, $383M to $696M
- Source: Matthew J. Higgins, Xin Yan, and Chirantan Chatterjee. "Unpacking the Effects of Adverse Regulatory Events: Evidence from Pharmaceutical Relabeling." Research Policy, 2021. https://doi.org/10.1016/j.respol.2020.104126
- Basis: Published abstract (RePEc): average loss $569M to $882M; affected products lose $186M.

### 26% of drug GMP warning letters cited process validation, the top violation

- Data (Drug GMP warning letters, 2010 to 2020):
  - Validation: 26%
  - Data integrity: 21%
  - Quality control: 15%
- Source: Anurag S. Rathore, Yuexia Li, Hemlata Chhabra, and Akshat Lohiya. "FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020." Journal of Pharmaceutical Innovation, 2022. https://doi.org/10.1007/s12247-022-09678-2
- Basis: Published abstract (Europe PMC PMC9377664).

### 65%+ of pharmaceutical warning letters went to companies in Asia, mostly India and China

- Data (Pharmaceutical warning letters, 2010 to 2020):
  - Asia, over 65%; Rest of world
- Source: Anurag S. Rathore, Yuexia Li, Hemlata Chhabra, and Akshat Lohiya. "FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020." Journal of Pharmaceutical Innovation, 2022. https://doi.org/10.1007/s12247-022-09678-2
- Basis: Published full text (Europe PMC PMC9377664).

### +32% industry compliance when most firms see each enforcement action

- Data (Simulation result. Compliance index, 25% visibility = 100.):
  - 25% see it: 100
  - 75% see it: 132
- Source: Yiyi Bao, Nicholas Buhay, and Qiang Zheng. "A Dynamic Model for GMP Compliance and Regulatory Science." Journal of Pharmaceutical Innovation, 2024. https://doi.org/10.1007/s12247-024-09825-x
- Basis: Published full text (open access, CC BY): simulation result.

### 43% more warning letters per 100 FDA inspections, 2019 to 2023

- Data (Warning letters per 100 inspections, all FDA centers):
  - 2019: 2.98
  - 2023: 4.27
- Source: George Kwiecinski. "An Analysis of FDA Warning Letter Citations from 2019-2023." Journal of Pharmaceutical Innovation, 2024. https://doi.org/10.1007/s12247-024-09879-x
- Basis: Published abstract and full text.

### 2.3× the rate of drug warning letters per 100 inspections, 2023 vs 2019

- Data (Drug warning letters per 100 inspections):
  - 2019: 2.97
  - 2023: 6.93
- Source: George Kwiecinski. "An Analysis of FDA Warning Letter Citations from 2019-2023." Journal of Pharmaceutical Innovation, 2024. https://doi.org/10.1007/s12247-024-09879-x
- Basis: Published full text: 2.97 (2019) and 6.93 (2023) per 100 inspections. 6.93 / 2.97 = 2.33.

### 37¢ more per month for a top generic if stronger quality checks raised its cost 25%

- Data (Pharmacy cost of a 30-day supply):
  - Under $1.50 today; +37¢
- Source: Marta E. Wosińska. "Rethinking Manufacturing Quality Oversight for Prescription Drugs." The Brookings Institution, 2025. https://www.brookings.edu/articles/rethinking-manufacturing-quality-oversight-for-prescription-drugs/
- Basis: Published article text (Brookings).

### 69.0% of FDA inspections in China ended with findings. The U.S. rate is 49.3%.

- Data (Inspections classified VAI or OAI):
  - U.S.: 49.3%
  - India: 62.3%
  - China: 69.0%
- Source: George Kwiecinski and Kevin Yuan. "The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014–2024." Journal of Pharmaceutical Innovation, 2026. https://doi.org/10.1007/s12247-026-10406-3
- Basis: Published abstract (Crossref), Conclusion.

## In progress

Rebuilding FDA's site selection model. Uses public data to show how FDA picks sites for inspection. By George Kwiecinski and co-authors.

## Look up FDA records, free, in KeyPedia Lite

- [Look up a site's FDA inspection history](https://www.keypedia.com/records/fda_inspections?utm_source=fdarisk&utm_medium=llms&utm_campaign=lookup&utm_content=inspections)
- [See what FDA found at a site](https://www.keypedia.com/records/483?utm_source=fdarisk&utm_medium=llms&utm_campaign=lookup&utm_content=483s)
- [Follow a supplier's FDA record](https://www.keypedia.com/auth/signup?source=fdarisk-lookup&utm_source=fdarisk&utm_medium=llms&utm_campaign=lookup&utm_content=follow-supplier)

## Papers cited

- Gopesh Anand, John V. Gray, and Enno Siemsen. "Decay, Shock, and Renewal: Operational Routines and Process Entropy in the Pharmaceutical Industry." Organization Science, 2012. https://doi.org/10.1287/orsc.1110.0709
- Matthew J. Higgins, Xin Yan, and Chirantan Chatterjee. "Unpacking the Effects of Adverse Regulatory Events: Evidence from Pharmaceutical Relabeling." Research Policy, 2021. https://doi.org/10.1016/j.respol.2020.104126
- Anurag S. Rathore, Yuexia Li, Hemlata Chhabra, and Akshat Lohiya. "FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020." Journal of Pharmaceutical Innovation, 2022. https://doi.org/10.1007/s12247-022-09678-2
- Yiyi Bao, Nicholas Buhay, and Qiang Zheng. "A Dynamic Model for GMP Compliance and Regulatory Science." Journal of Pharmaceutical Innovation, 2024. https://doi.org/10.1007/s12247-024-09825-x
- George Kwiecinski. "An Analysis of FDA Warning Letter Citations from 2019-2023." Journal of Pharmaceutical Innovation, 2024. https://doi.org/10.1007/s12247-024-09879-x
- Marta E. Wosińska. "Rethinking Manufacturing Quality Oversight for Prescription Drugs." The Brookings Institution, 2025. https://www.brookings.edu/articles/rethinking-manufacturing-quality-oversight-for-prescription-drugs/
- George Kwiecinski and Kevin Yuan. "The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014–2024." Journal of Pharmaceutical Innovation, 2026. https://doi.org/10.1007/s12247-026-10406-3

## About

FDA Risk is powered by KeyPedia. The full KeyPedia research library is at https://www.keypedia.com/platform/documentation. KeyPedia's own site index for AI tools is at https://www.keypedia.com/llms.txt.